背景:高血压,一种流行的疾病,是冠心病的重要危险因素。活血千阳曲坦食谱(HQQR),一种传统的中草药,多年来一直被用于治疗高血压。
目的:本研究评估HQQR对血瘀型高血压患者血压控制的疗效。阳上亢痰。
方法:在岳阳市中西医结合医院进行随机对照试验,上海中医药大学,中国,从2020年7月到2022年6月。使用薄层色谱法和高效液相色谱法鉴定了HQQR的主要成分。18-80岁的参与者,表现出中医血瘀证,阳多动或痰,连同1或2级高血压,随机分为两组。干预组在常规高血压治疗的同时给予HQQR颗粒,对照组在常规治疗的基础上给予安慰剂颗粒,疗程12周。
方法:主要结果是临床血压,而次要结果包括代谢指数(例如,胰岛素抵抗的稳态模型评估[HOMA-IR],总胆固醇[TC],低密度脂蛋白胆固醇和甘油三酯),靶器官损害指数(左心室质量指数和尿白蛋白肌酐比值[UACR])和炎症指数(白细胞介素-6[IL-6]和高敏C反应蛋白[hs-CRP])。
结果:HQQR的主要成分被确定为丹酚酸B,大黄素和阿魏酸.在216名参与者中(每组108名),与对照相比,干预组临床收缩压([136.24±7.63]vs[130.06±8.50]mmHg)显著改善(P<0.001),临床舒张压([84.34±8.72]vs[80.46±6.05]mmHg),家庭收缩压([131.64±8.74]vs[122.36±8.45]mmHg)和家庭舒张压([78.47±9.53]vs[71.79±6.82]mmHg)。HQQR显示动态血压降低(24小时收缩压:[133.75±10.49]vs[132.46±8.84]mmHg和24小时舒张压:[84.12±8.01]vs[82.11±7.45]mmHg),HOMA-IR改善([4.09±1.72]vs[3.98±1.44]),TC([4.66±1.47]vs[3.75±1.81]mmol/L)和UACR(75.94[5.12,401.12]vs45.61[4.26,234.26])。此外,HQQR显示hs-CRP(1.46[0.10,10.53]vs0.57[0.12,3.99]mg/L)和IL-6(6.69[2.00,29.74]vs5.27[2.00,9.73]pg/mL)下降,没有报道的副作用(P<0.001)。
结论:本研究强调了HQQR在改善血压方面的治疗潜力,糖脂代谢,高血压患者的炎症。
背景:ChiCTR2000035092(https://www.chictr.org.cn/)。请引用这篇文章:谢杰,MaYL,GuiMT,姚L,李杰,WangMZ,周XJ,王YF,赵米,曹H,LuB,FuDY.活血潜阳祛痰方治疗原发性高血压的随机对照研究,双盲,安慰剂对照试验。JIntegrMed。2024年;Epub提前打印。
BACKGROUND: Hypertension, a prevalent disease, is a significant risk factor for coronary heart disease. Huoxue Qianyang Qutan Recipe (HQQR), a traditional Chinese herbal remedy, has been used for treating hypertension over several years.
OBJECTIVE: This study assesses HQQR\'s efficacy for controlling blood pressure among patients with hypertension related to blood stasis, yang hyperactivity and phlegm.
METHODS: A randomized controlled trial was conducted at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, China, from July 2020 to June 2022. Major components of HQQR were identified using thin-layer chromatography and high-performance liquid chromatography. Participants aged 18-80 years, exhibiting traditional Chinese medicine syndromes of blood stasis, yang hyperactivity or phlegm, along with grades 1 or 2 hypertension, were randomly categorized into two groups. The intervention group was given HQQR granules alongside conventional hypertension treatment, while the control group was given placebo granules in addition to conventional treatment for 12 weeks.
METHODS: The primary outcome was clinic blood pressure, whereas secondary outcomes included metabolic indices (e.g., homeostasis model assessment of insulin resistance [HOMA-IR], total cholesterol [TC], low-density lipoprotein cholesterol and triglyceride), target organ damage indices (left ventricular mass index and urinary albumin creatinine ratio [UACR]) and inflammation indices (interleukin-6 [IL-6] and high-sensitivity C-reactive protein [hs-CRP]).
RESULTS: HQQR\'s primary components were identified as salvianolic acid B, emodin and ferulic acid. Of the 216 participants (108 in each group), compared to the control, the intervention group exhibited significant improvements (P < 0.001) in clinic systolic blood pressure ([136.24 ± 7.63] vs [130.06 ± 8.50] mmHg), clinic diastolic blood pressure ([84.34 ± 8.72] vs [80.46 ± 6.05] mmHg), home systolic blood pressure ([131.64 ± 8.74] vs [122.36 ± 8.45] mmHg) and home diastolic blood pressure ([78.47 ± 9.53] vs [71.79 ± 6.82] mmHg). HQQR demonstrated a reduction in ambulatory blood pressure (24-hour systolic blood pressure: [133.75 ± 10.49] vs [132.46 ± 8.84] mmHg and 24-hour diastolic blood pressure: [84.12 ± 8.01] vs [82.11 ± 7.45] mmHg) and an improvement in HOMA-IR ([4.09 ± 1.72] vs [3.98 ± 1.44]), TC ([4.66 ± 1.47] vs [3.75 ± 1.81] mmol/L) and UACR (75.94 [5.12, 401.12] vs 45.61 [4.26, 234.26]). Moreover, HQQR demonstrated a decrease in hs-CRP (1.46 [0.10, 10.53] vs 0.57 [0.12, 3.99] mg/L) and IL-6 (6.69 [2.00, 29.74] vs 5.27 [2.00, 9.73] pg/mL), with no reported side effects (P < 0.001).
CONCLUSIONS: This study highlights the therapeutic potential of HQQR use in ameliorating blood pressure, glycolipid metabolism, and inflammation in patients with hypertension.
BACKGROUND: ChiCTR2000035092 (https://www.chictr.org.cn/). Please cite this article as: Xie J, Ma YL, Gui MT, Yao L, Li JH, Wang MZ, Zhou XJ, Wang YF, Zhao MY, Cao H, Lu B, Fu DY. Efficacy of Huoxue Qianyang Qutan Recipe on essential hypertension: A randomized, double-blind, placebo-controlled trial. J Integr Med 2024; 22(4): 485-493.